豨莶通栓胶囊联合西药治疗急性缺血性脑卒中的效果观察

Effect of Siegesxiantongshuan Capsule combined with Western medicine on acute ischemic stroke

目的:探讨联用豨莶通栓胶囊和西药治疗急性缺血性脑卒中的效果。方法:选取2019年2月至2020年2月期间中国中医科学院西苑医院收治的96例急性缺血性脑卒中患者作为研究对象。将这些患者分为对照组和观察组,每组各有48例患者。两组患者入院后,均为其常规使用西药进行治疗。在此基础上,为观察组患者加用豨莶通栓胶囊进行治疗。治疗12周后,对比两组患者的临床疗效、美国国立卫生研究院卒中量表(NIHSS)的评分、Barthel指数评定量表的评分、血小板的聚集率及不良反应的发生率。结果:观察组患者治疗的总有效率、治疗后Barthel指数评定量表的评分均高于对照组患者,P<0.05;其治疗后NIHSS的评分、血小板的聚集率均低于对照组患者,P<0.05。在治疗期间,两组患者不良反应的发生率相比,P>0.05。结论:联用豨莶通栓胶囊和西药治疗急性缺血性脑卒中的效果较为理想,可有效地提高此病患者的脑神经功能及生存质量,且安全性较高。

Objective:To explore the effect of treating acute ischemic stroke with Siegesxitongshuan Capsule and Western medicine.Methods:A total of 96 patients with acute ischemic stroke admitted to Xiyuan Hospital,China Academy of Chinese Medical Sciences from February 2019 to February 2020 were selected as the study subjects.These patients were divided into control group and observation group,with 48 patients in each group.After admission,both groups of patients were routinely treated with western medicine.On this basis,the observation group was treated with Siegesbeckiang Capsule.After 12 weeks of treatment,the clinical efficacy,NIHSS score,Barthel index score,platelet aggregation rate and incidence of adverse reactions were compared between the two groups.Results:The total effective rate and Barthel index score of the observation group were higher than those of the control group,P<0.05;After treatment,NIHSS score and platelet aggregation rate were lower than those of control group,P<0.05.During treatment,the incidence of adverse reactions in 2 groups was compared,P>0.05.Conclusion:The treatment of Acute ischemic stroke with Siegesxitongshuan Capsule and Western medicine had ideal effect,which could effectively improve the cerebral nerve function and quality of life of patients with this disease,with high safety.